Biotechnology company Dyno Therapeutics has launched from stealth mode with focus on using artificial intelligence (AI) technology to develop adeno-Associated Virus (AAV) vectors.
The company signed gene therapy deals with Novartis and Sarepta Therapeutics.
Dyno Therapeutics and Novartis will create improved AAV vectors for research, development and commercialisation of gene therapies across ocular diseases.
The partnership will leverage Dyno’s CapsidMap AI platform in combination with Novartis gene therapy development and global commercialisation expertise.
Dyno will use AI technology and its suite of machine learning and experimental tools to design and identify AAV capsids with improved functional properties for gene therapy.
Later, Novartis will carry out preclinical, clinical and commercialisation activities for the gene therapy candidates developed using the AAV capsids.
Dyno will gain upfront consideration, research funding, licence fees, along with potential clinical, regulatory and sales milestone payments.
Dyno Therapeutics CEO and co‑founder Eric Kelsic said: “With their extensive ophthalmologic expertise, Novartis is an ideal partner to leverage Dyno’s platform to design AI-powered vectors to expand the impact of gene therapies for ocular diseases.
“This collaboration is a major step forward in our plan to realise the potential of Dyno’s CapsidMap platform for gene therapies to improve patient health.”
Meanwhile, the company will work with Sarepta Therapeutics to use its CapsidMap platform to develop next-generation AAV vectors for muscle diseases.
Under the deal, Dyno will design and discover AAV capsids for gene therapy while Sarepta will conduct preclinical, clinical and commercialisation for product candidates resulting from the alliance.
Dyno could get more than $40m in upfront, option and licence payments during the research phase. Also, if Sarepta develops and commercialises product candidates for various muscle diseases, Dyno will receive milestone payments.